- Home
- RIV vs CDTX Comparison
RIV vs CDTX Comparison
Compare RIV & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIV
- CDTX
- Stock Information
- Founded
- RIV 2015
- CDTX 2012
- Country
- RIV United States
- CDTX United States
- Employees
- RIV N/A
- CDTX N/A
- Industry
- RIV Finance Companies
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RIV Finance
- CDTX Health Care
- Exchange
- RIV Nasdaq
- CDTX Nasdaq
- Market Cap
- RIV 264.7M
- CDTX 259.0M
- IPO Year
- RIV N/A
- CDTX 2015
- Fundamental
- Price
- RIV $10.92
- CDTX $19.44
- Analyst Decision
- RIV
- CDTX Strong Buy
- Analyst Count
- RIV 0
- CDTX 8
- Target Price
- RIV N/A
- CDTX $38.00
- AVG Volume (30 Days)
- RIV 87.6K
- CDTX 181.4K
- Earning Date
- RIV 01-01-0001
- CDTX 05-14-2025
- Dividend Yield
- RIV 12.85%
- CDTX N/A
- EPS Growth
- RIV N/A
- CDTX N/A
- EPS
- RIV N/A
- CDTX N/A
- Revenue
- RIV N/A
- CDTX $1,275,000.00
- Revenue This Year
- RIV N/A
- CDTX N/A
- Revenue Next Year
- RIV N/A
- CDTX N/A
- P/E Ratio
- RIV N/A
- CDTX N/A
- Revenue Growth
- RIV N/A
- CDTX N/A
- 52 Week Low
- RIV $9.63
- CDTX $10.00
- 52 Week High
- RIV $12.43
- CDTX $28.42
- Technical
- Relative Strength Index (RSI)
- RIV 37.13
- CDTX 48.18
- Support Level
- RIV $10.79
- CDTX $15.76
- Resistance Level
- RIV $11.25
- CDTX $20.17
- Average True Range (ATR)
- RIV 0.42
- CDTX 1.51
- MACD
- RIV -0.02
- CDTX 0.20
- Stochastic Oscillator
- RIV 43.81
- CDTX 56.87
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.